EAM
CLRB icon

Empery Asset Management’s Cellectar Biosciences CLRB Stock Holding History

Empery Asset Management’s Portfolio CLRB Stock Details CLRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$527K Buy
+189,605
New +$530K 0.61% 17

Other funds holding CLRB

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
PAP
Persistent Asset Partners Hong Kong $335M AUM 275.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
RCA
Riverview Capital Advisers Boston, Massachusetts $349M AUM 33.11% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Empery Asset Management's CLRB Position: Q2 2026 in Review

Empery Asset Management opened a new position in Cellectar Biosciences (CLRB) in Q2 2026: 189,605 shares worth $527K. The stake represents 0.61% of the portfolio and ranks #17 among its holdings.

18 funds tracked by Wall St. Rank hold CLRB as of Q2 2026.

  • Empery Asset Management held 189,605 shares of Cellectar Biosciences worth $527K as of Q2 2026.
  • Cellectar Biosciences was a new Empery Asset Management position in Q2 2026.
  • Cellectar Biosciences made up 0.61% of Empery Asset Management's portfolio in Q2 2026, its #17 holding.
  • 18 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q2 2026.

Based on Empery Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.